CL2023002321A1 - Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. - Google Patents
Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia.Info
- Publication number
- CL2023002321A1 CL2023002321A1 CL2023002321A CL2023002321A CL2023002321A1 CL 2023002321 A1 CL2023002321 A1 CL 2023002321A1 CL 2023002321 A CL2023002321 A CL 2023002321A CL 2023002321 A CL2023002321 A CL 2023002321A CL 2023002321 A1 CL2023002321 A1 CL 2023002321A1
- Authority
- CL
- Chile
- Prior art keywords
- anhedonia
- treatment
- voltage
- potassium channel
- channel opener
- Prior art date
Links
- 208000007415 Anhedonia Diseases 0.000 title abstract 3
- 150000003109 potassium Chemical class 0.000 title 1
- 239000004036 potassium channel stimulating agent Substances 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- FJNPZKZPWVVSON-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 FJNPZKZPWVVSON-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Shovels (AREA)
- Ignition Installations For Internal Combustion Engines (AREA)
Abstract
La presente divulgación está dirigida, entre otras cosas, a métodos y usos para tratar la anhedonia en un sujeto, como un ser humano, en los que los métodos comprenden administrar una cantidad terapéuticamente eficaz de N-[4-(6- fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A) al sujeto que lo necesita, y los usos comprenden el Compuesto A para usar en el tratamiento de la anhedonia en un sujeto, tal como humano La presente divulgación se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147742P | 2021-02-09 | 2021-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002321A1 true CL2023002321A1 (es) | 2024-03-08 |
Family
ID=80445983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002321A CL2023002321A1 (es) | 2021-02-09 | 2023-08-07 | Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11957675B2 (es) |
| EP (1) | EP4291189A1 (es) |
| JP (1) | JP2024508660A (es) |
| KR (1) | KR20240004241A (es) |
| CN (1) | CN116847843A (es) |
| AU (1) | AU2022220675A1 (es) |
| CA (1) | CA3207191A1 (es) |
| CL (1) | CL2023002321A1 (es) |
| IL (1) | IL304920A (es) |
| MA (1) | MA61732A1 (es) |
| MX (1) | MX2023009314A (es) |
| TW (1) | TW202245744A (es) |
| WO (1) | WO2022173855A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220288057A1 (en) * | 2021-02-09 | 2022-09-15 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650853A1 (en) | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
| ES2420960T3 (es) | 2006-08-23 | 2013-08-28 | Valeant Pharmaceuticals International | Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio |
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| MX2010001171A (es) * | 2007-08-01 | 2010-03-01 | Lundbeck & Co As H | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico. |
| HRP20231447T1 (hr) * | 2018-05-11 | 2024-03-01 | Xenon Pharmaceuticals Inc. | Postupci za povećanje bioraspoloživosti i izloženosti naponski upravljanog otvarača kalijevih kanala |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| MX2022005490A (es) * | 2019-11-08 | 2022-08-10 | Xenon Pharmaceuticals Inc | Metodos para el tratamiento de trastornos depresivos. |
| EP4069226A4 (en) * | 2019-12-06 | 2023-12-27 | Icahn School of Medicine at Mount Sinai | TREATMENT METHOD WITH KCNQ CHANNEL ACTIVATORS |
-
2022
- 2022-02-09 CA CA3207191A patent/CA3207191A1/en active Pending
- 2022-02-09 US US17/668,340 patent/US11957675B2/en active Active
- 2022-02-09 AU AU2022220675A patent/AU2022220675A1/en active Pending
- 2022-02-09 MA MA61732A patent/MA61732A1/fr unknown
- 2022-02-09 EP EP22705687.6A patent/EP4291189A1/en active Pending
- 2022-02-09 JP JP2023547490A patent/JP2024508660A/ja active Pending
- 2022-02-09 MX MX2023009314A patent/MX2023009314A/es unknown
- 2022-02-09 KR KR1020237030629A patent/KR20240004241A/ko unknown
- 2022-02-09 IL IL304920A patent/IL304920A/en unknown
- 2022-02-09 CN CN202280014279.1A patent/CN116847843A/zh active Pending
- 2022-02-09 TW TW111104798A patent/TW202245744A/zh unknown
- 2022-02-09 WO PCT/US2022/015854 patent/WO2022173855A1/en active Application Filing
-
2023
- 2023-08-07 CL CL2023002321A patent/CL2023002321A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240004241A (ko) | 2024-01-11 |
| MA61732A1 (fr) | 2024-01-31 |
| WO2022173855A1 (en) | 2022-08-18 |
| MX2023009314A (es) | 2023-08-16 |
| CN116847843A (zh) | 2023-10-03 |
| AU2022220675A1 (en) | 2023-09-21 |
| US20220265634A1 (en) | 2022-08-25 |
| CA3207191A1 (en) | 2022-08-18 |
| US11957675B2 (en) | 2024-04-16 |
| JP2024508660A (ja) | 2024-02-28 |
| IL304920A (en) | 2023-10-01 |
| EP4291189A1 (en) | 2023-12-20 |
| TW202245744A (zh) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002321A1 (es) | Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CL2021002965A1 (es) | Compuestos antivirales que contienen nitrilo. | |
| CO2020015476A2 (es) | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje | |
| CL2022001477A1 (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor | |
| CO2023000703A2 (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| ECSP23048974A (es) | Compuesto de heteroarilcarboxamida | |
| CL2022002566A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| CO2024001102A2 (es) | Compuestos de pirazolopiridinona | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2024004994A (es) | Métodos para tratar el cáncer de ovário con extracto de cáñamo. | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| CL2023002323A1 (es) | Terapia conjunta para el tratamiento de trastornos convulsivos | |
| PE20230386A1 (es) | Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e | |
| AR121518A1 (es) | Métodos para usar rebastinib en el tratamiento de trastornos | |
| EA202091968A1 (ru) | Составы эпинефрина в виде спрея | |
| CL2022003031A1 (es) | Composicion que comprende albumina para su utilizacion en el tratamiento de la esclerosis lateral amiotrofica (ela) mediante recambio plasmatico | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| PE20230181A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso |